Stem Cell Therapy in Traumatic Brain Injury

Phase 1WithdrawnNCT02028104

Neurogen Brain and Spine Institute

Overview

The purpose of this study was to study the effect of stem cell therapy on common symptoms in patients with Traumatic Brain Injury

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Traumatic Brain Injury

Interventions

Autologous bone marrow mononuclear cell transplantationBIOLOGICAL

bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed cases of chronic traumatic brain injury * Age above 6 months Exclusion Criteria: * presence of acute infections such as Human immunodeficiency virus/Hepatitis B - Virus/Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia * pregnancy * lactation

Locations (1)

Neurogen brain and spine institute

Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Change in clinical symptoms of traumatic brain injury

Time frame: 6 months

Secondary Outcomes

Disability Rating scale

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.